Targeting IGF1R pathway in cancer with microRNAs: How close are we?

RNA Biol. 2018 Mar 4;15(3):320-326. doi: 10.1080/15476286.2017.1338240. Epub 2018 Feb 1.

Abstract

Cancer of the head and neck are the most common cancers in India and account for 30% of all cancers. At molecular level, it could be attributed to the overexpression of growth factors like IGF1-R, EGFR, VEGF-R and deregulation of cell cycle regulators and tumor suppressors. IGF1-R is an emerging target in head and neck cancer treatment, because of its reported role in tumor development, progression and metastasis. IGF1R targeted agents are in advanced stages of clinical development. Nevertheless, these agents suffer from several disadvantages including acquired resistance and toxic side effects. Hence there is a need for developing newer agents targeting not only the receptor but also its downstream signaling. miRNAs are considered as master regulators of gene expression of multiple genes and has been widely reported to be a promising therapeutic strategy. This review discusses the present status of research in both these arenas and emphasizes the role of miRNA as a promising agent for biologic therapy.

Keywords: Growth factor receptor signaling; IGF1R; head neck cancer; miR493; miRNA therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Male
  • MicroRNAs / drug effects
  • MicroRNAs / genetics*
  • Molecular Targeted Therapy
  • Neoplasms / genetics*
  • Receptor, IGF Type 1
  • Receptors, Somatomedin / genetics
  • Receptors, Somatomedin / metabolism*
  • Signal Transduction / drug effects

Substances

  • Antineoplastic Agents
  • IGF1R protein, human
  • MicroRNAs
  • Receptors, Somatomedin
  • Receptor, IGF Type 1

Grants and funding

RSK was supported by a grant from Department of Biotechnology, Ministry of Science & Technology, Govt of India via grant No. BT/PR12930/AGR/36/650/2009. ASK is thankful to Council of Scientific and Industrial Research, Govt of India for research fellowship.